LBO — ASPIRUS RIVERVIEW HOSPITAL & CLINICS
IRR: 16.1% | MOIC: 2.11x
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
16.1%
IRR
2.11x
MOIC
$217.0M
Entry EV
$320.7M
Exit EV
$111.7M
Equity Invested
Sources & Uses
S&UTotal · $217.0M| Item | Amount | % | Distribution |
|---|---|---|---|
| Senior Debt | $84.3M | 38.8% | |
| Sub Debt | $21.1M | 9.7% | |
| Equity | $111.7M | 51.5% | |
| Enterprise Value | $210.7M | 97.1% | |
| Transaction Fees | $6.3M | 2.9% | |
| Total Uses | $217.0M | 100.0% |
Interpretation
INTAt 2.11x MOIC and 16.1% IRR over 5 years, this deal meets the 15-20% range — acceptable with operational upside.
Key drivers: Check the EBITDA bridge to identify highest-probability levers, the debt schedule for leverage trajectory, or the challenge solver to see what breaks the deal.
Returns Waterfall
WFL| Component | Value |
|---|---|
| Exit Ebitda | $30.5M |
| Exit Ev | $320.7M |
| Net Debt At Exit | $85.0M |
| Equity At Exit | $235.7M |
| Equity Invested | $111.7M |
| Total Value Created | $124.0M |
| Value From Growth | $99.4M |
| Value From Multiple | $10.5M |
| Value From Deleveraging | $20.3M |